Prostiva® RF Therapy

Prostiva® RF Therapy (Prostiva) is a safe, effective, in-office treatment that that provides long-term relief from BPH symptoms and urinary obstruction. Prostiva is appropriate for men experiencing moderate to severe BPH symptoms especially patients who do not want to take daily medications for the rest of their lives, dislike the side effects and ongoing costs of medication or do not want the risks, side effects or high costs of surgery.

Because it provides direct visualization of the anatomy during the procedure, Prostiva treats the median and lateral lobe as well as asymmetrical prostates.  Here are some examples of prostate shapes that Prostiva® RF Therapy can treat:


How Does it Work?

Prostiva® RF Therapy treats BPH utilizing low level radio frequency energy to destroy enlarged prostate tissue. The movement of the electrons causes the tissue to heat.  One reason RF energy has been so effective in forming precise and controlled lesions is the existence of a phenomenon called current density. Current density is the amount of current flowing out of the surface area of the conductor. As the current is emitted from the needle electrodes, the energy is concentrated along the small exposed surfaces of the electrodes, creating a very high current density at the electrode surface. The energy quickly dissipates as it leaves the needle electrodes on its path to the grounding pad. This produces predictable and repeatable lesions, which are located directly around the electrodes. The Prostiva® RF Therapy procedure helps to reduce the constriction of the urethra and relieve BPH voiding symptoms.

Prostiva RF Therapy provides significant benefits to you, your practice, and most importantly your patients.

  • Relief from the uncomfortable, systematic effects of BPH drugs
  • Convenient treatment completed in your office generally in one to one and a half hours (including preparation and recovery time)
  • Minimally invasive treatment which does not require general anesthesia
  • 360 degrees of precision to treat exactly the area you want
  • Six different needle length options to treat varying prostate sizes and shapes
  • 15 computer-monitored safety checks
  • Effective results – clinically significant improvements in IPSS, peak uroflow, and quality of life at five years1
  • Durable results – reintervention not necessary in over 86% of patients at five years1
  • Low rate of side effects1
  • Established reimbursement

For more complete information about the benefits and risks associated with Prositva® RF Therapy, please refer to the Prostiva® RF Therapy System Guide (14MB PDF).

Try Prostiva RF in-office therapy

Urologix offers all doctors an opportunity to try Prostiva RF at a great rate to allow you to see how great the treatment really is. Please contact us for more information.

Clinical Results

Prostiva® RF Therapy has currently has currently treated over 100,000 patients worldwide and there have been at least 75 published articles on RF Therapy for BPH. For a complete overview of the Prostiva® RF Therapy clinical data, please go to our Clinical Results page.

Increased Necrosis, Greater Durability3,4

It’s proven.  More tissue necrosis equates to a better long-term outcome for patients.  Tissue necrosis is a function of time and temperature.  50°C is required to produce tissue necrosis in 60 minutes, higher temperatures produce a larger volume of necrosis in less time.  Treatment times at temperatures below injury threshold produce no irreversible damage.  Prostiva® RF Therapy reaches intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue in just two minutes and 20 seconds.

1Hill, B., et al Transurethreal Needle Ablation vs TURP for the Treatment of Symptomatic BPH: 5 Year Results of a Prospective, Randomized, Multicenter Clinical Trial, Journal of Urology Vol 171, 2336-2340, June 2004 2Data derived from the Prostiva RF Therapy System User Guide 8930 CRMRef_R06 3Larson, T, et al., Detailed Interstitial Temperature Mapping During TUMT Treatment for BPH, Journal of Urology, January 2998 4Bhowmick, P., et al, In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia, Int. J Hyperthermia, Vol 20, No 4, June 2004, pp 421-39.